Meeting
2012 Breast Cancer Symposium
Chemotherapy treatment patterns for early-stage breast cancer (ESBC): Decreasing use of anthracycline-based regimens.
Authors
Katherine Serrurier
University of California, San Francisco Helen Dill
Katherine Serrurier , Jimmy Hwang , Joseph McGuire , Ann Griffin , Michelle Melisko , Hope Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Survivorship and Health Policy,Systemic Therapy,Local/Regional Therapy
Sub Track
Triple-Negative
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 141)
DOI
10.1200/jco.2012.30.27_suppl.141
Abstract #
141
Poster Bd #
C17
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2015 Breast Cancer Symposium
Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH).
First Author: Rosana Gnanajothy
Poster
2014 ASCO Annual Meeting
Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).
First Author: Ines Maria Vaz Duarte Luis